Citations

Clear

59 citation(s) found for "Reed, Ann".

Multiomics alterations associated with tolerance and response to simulated progressive hemorrhage in healthy adult humans
Misganaw, Burook , Muhie, Seid , Gautam, Aarti , Miller, Stacy-Ann, Rosales, I. C. Bonilla, Dimitrov, George I., Sowe, Bintu, Johnson, Christopher P., Roberts, Shelly K., Regimbal, Riley J. , Wiggins, Chad C. , CONVERTINO, V, Joyner, Michael J , Curry, Timothy B. , Hammamieh, Rasha , Wiggins, Chad C , Gautam, Aarti, Miller, Stacy‐Ann , Dimitrov, George I., Johnson, Christopher P., Joyner, Michael J. , Convertino, Víctor A.

Mayo Clinic

Physiological Genomics | January 7, 2026 | Volume: 58 | Issue: 2 | Pages: 102-114

10.1152/physiolgenomics.00253.2025 | PMID 41494644 Get It

This study investigated the first multiomics data for association with tolerance to central hypovolemia in humans. Analyzing gene expression, proteins, and genetic variants in individuals with high and low tolerance to simulated hemorrhage, the findings show that severe blood loss causes widespread transcriptional changes, including the activation of innate immune system pathways and inhibition of gas transport processes. This research can help identify molecular factors that influence individuals’ tolerance levels for progressive blood loss.
Gene Expression Profiles of Treatment Response and Non‐Response in Children With Juvenile Dermatomyositis
Stingl, Cory , Dvergsten, Jeffrey , Eng, Simon , Mason, Thomas G. , Crowson, Cynthia S. , Reed, Ann M. , Mason, Thomas, Crowson, CS , Reed, Ann M , Eng, Simon W M , Yeung, Rae S. M. , Fritzler, Marvin J. , Mason, Thomas, Voora, Deepak

Mayo Clinic

ACR Open Rheumatology | May 26, 2022 | Volume: 4 | Issue: 8 | Pages: 671-681

10.1002/acr2.11445 | PMID 35616642 Get It

ObjectiveThe study objective was to identify differences in gene expression between treatment responders (TRs) and treatment non‐responders (TNRs) diagnosed with juvenile dermatomyositis (JDM).MethodsGene expression analyses were performed using whole blood messenger RNA sequencing in patients with JDM (n = 17) and healthy controls (HCs; n = 10). Four analyses were performed (A1‐4) comparing differential gene expression and pathways analysis exploiting the timing of sample acquisition and the treatments received to perform these comparative analyses. Analyses were done at diagnosis and follow‐up, which averaged 7 months later in the cohort.ResultsAt diagnosis, the expression of 10 genes differed between TRs and TNRs. Hallmark and canonical pathway analysis revealed 11 and 60 pathways enriched in TRs and 3 and 21 pathways enriched in TNRs, respectively. Pathway enrichment at diagnosis in TRs was strongest in pathways involved in metabolism, complement activation, and cell signaling as mediated by IL‐8, p38/microtubule associated protein kinases (MAPK)/extracellular signal‐regulated kinases (ERK), Phosphatidylinositol 3 Kinase Gamma (PI3Kγ), and the B cell receptor. Follow‐up hallmark and canonical pathway analysis showed that 2 and 14 pathways were enriched in TRs, whereas 24 and 123 pathways were enriched in treatment TNRs, respectively. Prior treatment with glucocorticoids significantly altered expression of 13 genes in the analysis of subjects at diagnosis with JDM as compared with HCs.ConclusionNumerous genes and pathways differ between TRs and TNRs at diagnosis and follow‐up. Prior treatment with glucocorticoids prior to specimen acquisition had a small effect on the performed analyses.
A Clinically and Biologically Based Subclassification of the Idiopathic Inflammatory Myopathies Using Machine Learning
Eng, Simon , Olazagasti, Jeannette M., Crowson, Cynthia S. , Niewold, Timothy B. , Yeung, Rae S. M. , Reed, Ann M. , Eng, Simon W M , Crowson, CS , Yeung, Rae S M , Reed, Ann M , Goldenberg, Anna , Oddis, Chester V.

Mayo Clinic

ACR Open Rheumatology | February 10, 2020 | Volume: 2 | Issue: 3 | Pages: 158-166

10.1002/acr2.11115 | PMID 32039563 Get It

ObjectivePublished predictive models of disease outcomes in idiopathic inflammatory myopathies (IIMs) are sparse and of limited accuracy due to disease heterogeneity. Computational methods may address this heterogeneity by partitioning patients based on clinical and biological phenotype.MethodsTo identify new patient groups, we applied similarity network fusion (SNF) to clinical and biological data from 168 patients with myositis (64 adult polymyositis [PM], 65 adult dermatomyositis [DM], and 39 juvenile DM [JDM]) in the Rituximab in Myositis trial. We generated a sparse proof‐of‐concept bedside classifier using multinomial regression and identified characteristics that distinguished these groups. We conducted χ2 tests to link new patient groups with the myositis subtypes.ResultsSNF identified five patient groups in the discovery cohort that subdivided the myositis subtypes. The sparse multinomial regressor to predict patient group assignments (areas under the receiver operating characteristic curve = [0.78, 0.97]; areas under the precision‐recall curve = [0.55, 0.96]) found that autoantibody enrichment defined four of these groups: anti–Mi‐2, anti–signal recognition peptide (SRP), anti–nuclear matrix protein 2 (NXP2), and anti‐synthetase (Syn). Depletion of immunoglobulin M (IgM) defined the fifth group. Each group was associated with one subtype, with adult DM being associated with anti–Mi‐2 and anti‐Syn autoantibodies, JDM being associated with anti‐NXP2 autoantibodies, and adult PM being associated with IgM depletion and anti‐SRP autoantibodies. These associations enabled us to further resolve the current myositis subtypes.ConclusionUsing unsupervised machine learning, we identified clinically and biologically homogeneous groups of patients with IIMs, forming the basis of an integrated disease classification based on both clinical and biological phenotype, thus validating other approaches and what has been previously described.
Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis
Crowson, Cynthia S. , Hein, Molly S., Pendegraft, Richard S., Strausbauch, Michael, Niewold, Timothy B. , Ernste, Floranne C. , Dvergsten, Jeffrey , Amin, Shreyasee , Muskardin, Theresa Wampler , Baechler, Emily C., Reed, Ann M. , Strausbauch, Michael A, Reed, Ann M , Peterson, Erik J

Mayo Clinic

ACR Open Rheumatology | April 11, 2019 | Volume: 1 | Issue: 2 | Pages: 83-89

10.1002/acr2.1011 | PMID 31777784 Get It

ObjectiveOur aim was to identify cytokines and chemokines in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) that predict changes in disease activity.MethodsMultiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of interferon (IFN)‐regulated chemokines and other pro‐ and anti‐inflammatory cytokines specific to differentiation of specific T‐cell and innate pathways. Cytokine scores were computed for IFNCK (IP‐10, MCP‐1), Th1 (IFNɣ, TNFα, and IL2), Th2 (IL4, IL10, IL12, and IL 13), Th17 (IL6, IL17, IL1β), macrophage (MIP‐1α, MIP‐1β, IL8), and regulatory (IL10, TNFα) factors. Spearman correlation and mixed models were used to examine whether cytokines at a previous visit predict change in disease activity at the next visit.ResultsThe study included 36 patients (16 DM and 20 JDM) with at least two visits (87 patient intervals between two visits). Mean age (SD) at inclusion was 56.9 (18.4) years for DM and 10.8 (6.6) years in JDM, 67% of patients were female, 89% Caucasian. The mean (SD) physician global, muscle and extra‐muscular disease activity Visual Analog Scale scores at inclusion were 41 (26), 36 (30), and 34 (21) mm, respectively. The change in IFN score from one visit to the next was associated with the change in physician global (P = 0.010) and extramuscular (P < 0.001) disease activity scores. Preliminary results revealed significant correlations of previous IFNCK score and IL‐6 with subsequent disease activity measures, but after adjustment for multiple visits per patient, these associations did not reach statistical significance.ConclusionThere is a potential relationship between IFNCK and other cytokine scores seen in adult and juvenile DM with future disease states.
Effects of nitric oxide synthase inhibition on cutaneous vasodilation during body heating in humans
Shastry, Shubha, Dietz, Niki M., Halliwill, John R. , Reed, Ann S., Joyner, Michael J. , Joyner, Michael J

Mayo Clinic

Journal of Applied Physiology | December 22, 2017 | Volume: 85 | Issue: 3 | Pages: 830-834

10.1152/jappl.1998.85.3.830 | PMID 9729554 Get It

We sought to examine further the potential role of nitric oxide (NO) in the neurally mediated cutaneous vasodilation in nonacral skin during body heating in humans. Six subjects were heated with a water-perfused suit while cutaneous blood flow was measured by using laser-Doppler flowmeters placed on both forearms. The NO synthase inhibitor NG-monomethyl-l-arginine (l-NMMA) was given selectively to one forearm via a brachial artery catheter after marked cutaneous vasodilation had been established. During body heating, oral temperature increased by 1.1 ± 0.1°C while heart rate increased by 30 ± 6 beats/min. Mean arterial pressure stayed constant at 84 ± 2 mmHg. In the experimental forearm, cutaneous vascular conductance (CVC; laser-Doppler) decreased to 86 ± 5% of the peak response to heating ( P < 0.05 vs. pre-l-NMMA values) afterl-NMMA infusion. In some subjects, l-NMMA caused CVC to fall by ∼30%; in others, it had little impact on the cutaneous circulation. CVC in the control arm showed a similar increase with heating, then stayed constant whilel-NMMA was given to the contralateral side. These results demonstrate that NO contributes modestly, but not consistently, to cutaneous vasodilation during body heating in humans. They also indicate that NO is not the only factor responsible for the dilation.
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
Bottai, Matteo , Tjärnlund, Anna, Santoni, Giola , Pilkington, Clarissa , Visser, Marianne de, Amato, Anthony A. , Barohn, Richard J., Liang, Matthew H. , Singh, Jasvinder A. , Arnardottir, Snjólaug, Chinoy, Hector , Dankó, Katalin , Dimachkie, Mazen M. , Torre, Ignacio García‐De La , Gordon, Patrick , Hayashi, Taichi, Katz, James D. , Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca , Olesinka, Marzena, Reed, Ann M. , Rutkowska‐Sak, Lidia , Sanner, Helga , Selva-O’Callaghan, Albert , Vencovský, Jiří , Ytterberg, Steven R. , Miller, Frederick W. , Rider, Lisa G. , Engelen, Baziel G.M. van , Huber, Adam M. , Mohammed, Reem , Singh, Jasvinder A , Vencovsky, Jiri , Mohammed, Reem W , Chinoy, Hector , Selva O'Callaghan, Albert , Werth, Victoria P. , Visser, Marianne de, Alfredsson, Lars , Aggarwal, Rohit , Cooper, Robert G. , Feldman, Brian Michael , Li, Yuhui , Oddis, Chester V. , Song, Yeong Wook , Lundberg, Ingrid E. , García-De La Torre, Ignacio , Dimachkie, Mazen M

Mayo Clinic

RMD Open | November 14, 2017 | Volume: 3 | Issue: 2 | Pages: e000507

10.1136/rmdopen-2017-000507 | PMID 29177080 Get It

Objective To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) and their major subgroups. Methods An international, multidisciplinary group of myositis experts produced a set of 93 potentially relevant variables to be tested for inclusion in the criteria. Rheumatology, dermatology, neurology and paediatric clinics worldwide collected data on 976 IIM cases (74% adults, 26% children) and 624 non-IIM comparator cases with mimicking conditions (82% adults, 18% children). The participating clinicians classified each case as IIM or non-IIM. Generally, the classification of any given patient was based on few variables, leaving remaining variables unmeasured. We investigated the strength of the association between all variables and between these and the disease status as determined by the physician. We considered three approaches: (1) a probability-score approach, (2) a sum-of-items approach criteria and (3) a classification-tree approach. Results The approaches yielded several candidate models that were scrutinised with respect to statistical performance and clinical relevance. The probability-score approach showed superior statistical performance and clinical practicability and was therefore preferred over the others. We developed a classification tree for subclassification of patients with IIM. A calculator for electronic devices, such as computers and smartphones, facilitates the use of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria. Conclusions The new EULAR/ACR classification criteria provide a patient’s probability of having IIM for use in clinical and research settings. The probability is based on a score obtained by summing the weights associated with a set of criteria items.
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
Tjärnlund, Anna, Bottai, Matteo , Pilkington, Clarissa , Visser, Marianne de, Amato, Anthony A. , Barohn, Richard J., Liang, Matthew H. , Arnardottir, Snjólaug, Chinoy, Hector , Dankó, Katalin , Dimachkie, Mazen M. , Torre, Ignacio García‐De La , Gordon, Patrick , Hayashi, Taichi, Katz, James D. , Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca , Olesińska, Marzena , Reed, Ann M. , Rutkowska‐Sak, Lidia , Sanner, Helga , Selva-O’Callaghan, Albert , Song, Yeong‐Wook, Vencovský, Jiří , Ytterberg, Steven R. , Miller, Frederick W. , Rider, Lisa G. , Vencovsky, Jiri , Chinoy, Hector , Selva O'Callaghan, Albert , Lundberg, Ingrid E. , Werth, Victoria P. , Visser, Marianne de, Alfredsson, Lars , Singh, Jasvinder A. , Aggarwal, Rohit , Cooper, Robert G. , Feldman, Brian Michael , Li, Yuhui , Oddis, Chester V. , Song, Yeong-Wook, García-De La Torre, Ignacio , Dimachkie, Mazen M

Mayo Clinic

Arthritis & Rheumatology | October 27, 2017 | Volume: 69 | Issue: 12 | Pages: 2271-2282

10.1002/art.40320 | PMID 29106061 Get It

Objective To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups. Methods Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria. Results Based on data from 976 IIM patients (74% adults; 26% children) and 624 non‐IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) “probable IIM,” had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to “definite IIM.” A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ≥50–<55% as “possible IIM.” Conclusion The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology, and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of “definite,” “probable,” and “possible” IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist
Garg, Megha, Chapelle, Dawn, Dancey, Paul , Herzog, Ronit, Rivas‐Chacon, Rafael, Muskardin, Theresa Wampler , Reed, Ann M. , Goldbach‐Mansky, Raphaela , Sanchez, Gina A. Montealegre , Muskardin, Theresa L Wampler, Jesus, Adriana A. de , Reynolds, James C.

Mayo Clinic

JCI Insight | August 16, 2017 | Volume: 2 | Issue: 16 | Pages: No page available

10.1172/jci.insight.94838 | PMID 28814674 Get It

BACKGROUND. Deficiency of IL-1 receptor antagonist (DIRA) is a rare autoinflammatory disease that presents with life-threatening systemic inflammation, aseptic multifocal osteomyelitis, and pustulosis responsive to IL-1–blocking treatment. This study was performed (a) to investigate rilonacept, a long-acting IL-1 inhibitor, in maintaining anakinra-induced inflammatory remission in DIRA patients, (b) to determine doses needed to maintain remission, and (c) to evaluate the safety and pharmacokinetics of rilonacept in young children (<12 years). METHODS. Six mutation-positive DIRA patients (children, ages 3–6 years), treated with daily anakinra, were enrolled into an open-label pilot study of subcutaneous rilonacept for 24 months. Clinical symptoms and inflammatory blood parameters were measured at all visits. A loading dose (4.4 mg/kg) was administered, followed by once weekly injections (2.2 mg/kg) for 12 months. Dose escalation (4.4 mg/kg) was allowed if inflammatory remission was not maintained. Subjects in remission at 12 months continued rilonacept for an additional 12 months. RESULTS. Five of six patients required dose escalation for findings of micropustules. Following dose escalation, all patients were in remission on weekly rilonacept administration, with stable laboratory parameters for the entire study period of 24 months. All children are growing at normal rates and have normal heights and weights. Quality of life improved while on rilonacept. No serious adverse events were reported. CONCLUSION. Rilonacept was found to maintain inflammatory remission in DIRA patients. The once weekly injection was well tolerated and correlated with increased quality of life, most likely related to the lack of daily injections. TRIAL REGISTRATION. ClinicalTrials.gov NCT01801449. FUNDING. NIH, NIAMS, and NIAID.
Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa
Santiago, Tania M. González, Zavialov, Andrey V. , Saarela, Janna , Seppänen, Mikko , Reed, Ann M. , Abraham, Roshini S. , Gibson, Lawrence E. , Gonzalez Santiago, Tania M

Mayo Clinic

JAMA Dermatology | July 1, 2015 | Volume: 151 | Issue: 11 | Pages: 1230

10.1001/jamadermatol.2015.1635 | PMID 26131734 Get It

Mineral Oil Aspiration Related Juvenile Idiopathic Arthritis
Nelson, Andrew D. , Reed, Ann M. , Wylam, Mark E. , Fischer, Philip R.

Mayo Clinic

Case Reports in Pulmonology | June 11, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-3

10.1155/2015/403109 | PMID 26171269 Get It

We describe the development of rheumatoid factor-positive migratory polyarthritis in a 5-year-old male who had been administered bidaily oral mineral oil as a laxative since birth. Minor respiratory symptoms, radiographic and bronchoscopic findings were consistent with chronic lipoid pneumonia. We speculate that immune sensitization to mineral oil promoted the clinical syndrome of juvenile idiopathic arthritis.